NCT06660381
Psilocybin-assisted Treatment for Cannabis Use Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 24 words Show 5 more changesShow less
- Enrollment closed, study ongoing
- Study completion pushed from Dec 2026 to Feb 2027
- Primary completion date changed from estimate of Nov 2026 to Oct 21, 2026
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised
- Notable Primary completion date: Mar 2026 to Nov 2026
- Study completion date: Sep 2026 to Dec 2026
- Minor Secondary endpoints: details revised at 2 of 2 entries
- Study description revised
- Minor Primary completion date: Dec 2025 to Mar 2026
- Study completion date: Jun 2026 to Sep 2026
- Start date changed from estimate of Nov 2024 to Nov 8, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Self-reported cannabis use as assessed by a modified Timeline Follow-Back interview
Timeframe: Baseline, weekly up to 3 months
Biomarkers of recent cannabis use
Timeframe: Baseline, 3 months
Secondary (2)
Beck Depression Inventory-II (BDI-II) score
Pittsburgh Sleep Quality Index (PSQI) score
Arms and interventions
PsilocybinExperimental
Open-label psilocybin will be administered with psychological support to each participant at two dosing sessions approximately 2 weeks apart.
Drugs: Psilocybin
Sites
1 site in 1 country
- Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States